Do the Hallmarks of Aging Make SENS? (Part Two)

A supporter asks if the Hallmarks of Aging could effectively be substituted for the seven categories of cellular and molecular damage in the SENS platform. The answer is ‘no,’ because the Hallmarks include both too much and too little, and most importantly because the Hallmarks fail to serve as a roadmap toward the biomedical postponement of aging.

Read more...

Do the Hallmarks of Aging Make SENS? (Part One)

A supporter asks if the Hallmarks of Aging could effectively be substituted for the seven categories of cellular and molecular damage in the SENS platform. The answer is ‘no,’ because the Hallmarks include both too much and too little, and most importantly because the Hallmarks fail to serve as a roadmap toward the biomedical postponement of aging.

Read more...

Senolytics in Aging Muscle: Could the Cure Be Worse than the Disease?

Skeletal muscles are organized into long fibers, and when a fiber breaks the entire fiber is often lost. This made a supporter worry that senolytic therapies might break a muscle fiber and eliminate precious fibers in aging muscles. It appears that the injury at the heart of the questioner’s worry does not happen in practice.

Read more...

More Studies on Metformin and Survival

In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.

Read more...

Sponsor a Student

SENS Research Foundation (SRF) is launching its campaign Sponsor a Student to increase charitable donations that will allow it to hire more student researchers and teach them that aging is not indisputable. Sponsoring a student dramatically transforms a young person’s life, giving them a chance to conduct world-class research and learn more about the career that awaits them.

Read more...

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.

Read more...

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.

Read more...

An Oil Change is Not a Gasket Change: Insights from the Interaction of “Old Blood” and Senolytic Therapy

When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can